©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Direct Binding of C-terminal Region of p130 to SH2 and SH3 Domains of Src Kinase (*)

(Received for publication, November 16, 1995)

Tetsuya Nakamoto (1) (2) Ryuichi Sakai (1) Keiya Ozawa (1) Yoshio Yazaki (2) Hisamaru Hirai (2)(§)

From the  (1)Molecular Biology Division, Jichi Medical School, 3311-1 Yakushiji, Minami-Kawachi-machi, Kawachi-gun, Tochigi, 329-04 Japan and the (2)Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113, Japan

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

p130 is a major tyrosine-phosphorylated protein that tightly binds v-Crk in v-crk-transformed cells and v-Src in v-src-transformed cells. The ``substrate domain'' of p130 contains 15 possible Src homology (SH) 2-binding motifs, most of which conform to the binding motif for the Crk SH2 domain. Another region near its C terminus contains possible binding motifs for the Src SH2 domain and proline-rich sequences that are candidates for SH3-binding sites.

Using GST fusion proteins, we revealed that both SH2 and SH3 domains of Src bind p130, whereas v-Crk binds p130 through its SH2 domain. We located the binding site of p130 for the Src SH3 domain at the sequence RPLPSPP in the region near its C terminus. Mutations within this sequence or at Tyr of p130 caused a significant reduction in the association of p130 with Src, and no association was detected when both of them were deleted. The kinase activity in v-Crk-transformed cells was also associated with p130 through this region. On the other hand, the deletion of the substrate domain abolished the binding with v-Crk. The association through the C-terminal region of p130 with Src kinase may facilitate effective hyperphosphorylation of tyrosine residues in the substrate domain of p130, resulting in the binding of SH2-containing molecules to p130.


INTRODUCTION

Src family cytoplasmic tyrosine kinases, including Src, Fyn, and Lyn, possess conserved, noncatalytic, and regulatory domains named Src homology 2 (SH2) (^1)and Src homology 3 (SH3) domains. SH2 domains are composed of 100 amino acids and specifically interact with sequences containing phosphotyrosine(1, 2, 3) . SH3 domains are composed of 50 amino acids and interact with proline-rich amino acid sequences(1, 2, 3, 4) . These SH2 and SH3 domains exert their functions, e.g. regulating their own kinase activity(5, 6, 7) , connecting other signaling molecules to tyrosine kinases(8, 9, 10) , and locating the proteins to the site of cytoskeleton (11) , by inter- or intramolecular association with specific polypeptide sequences.

The SH2 and SH3 domains are also found in many signaling molecules other than Src family tyrosine kinases. Among them, proteins called ``adapter proteins'' such as Crk(2) , Nck(12) , and Grb2/Ash/Sem-5 (13, 14, 15) have only SH2 and SH3 domains and no catalytic domain. v-Crk, a transforming oncoprotein encoded by avian sarcoma viruses, is a fusion protein of viral gag protein and the SH2 and SH3 domains derived from c-Crk, a cellular counterpart of v-Crk(2) . v-Crk has an oncogenic potential and induces tyrosine phosphorylation of several proteins when expressed in fibroblasts, although the mechanism of phosphorylation is unknown. The most prominent tyrosine-phosphorylated protein among them is p130, which forms a tight complex with v-Crk(2, 16, 17) . We recently cloned the cDNA for p130 and named its product as p130 ( Crk-associated substrate)(18, 19) . On the other hand, activated forms of Src tyrosine kinase, e.g. v-Src and 527F-c-Src, are known to induce tyrosine phosphorylation of several cellular proteins(20, 21) . One of the major tyrosine-phosphorylated proteins, p130, appears in v-Src-transformed cells and is known to bind Src(20, 22, 23, 24) . Using the peptidase mapping analysis, we demonstrated that the p130 associated with v-Src is identical to p130(18) . Although the phosphorylation of p130 was shown to closely correlate with the transformation in NIH 3T3 cells(18) , the mechanism of phosphorylation of p130 is unclear.

The primary structure of p130 reveals that it has a proline-rich region and several tyrosine residues near its C terminus (18) , and that these motifs fairly well conform to the consensus binding sequences for the SH2 and SH3 domains of Src. Moreover, it has 15 YXXP motifs following its own SH3 domain(18) . Many of these YXXP motifs are estimated to be ideal substrates for cytoplasmic tyrosine kinases (25) and are very close to the consensus binding motif for the Crk SH2 domain(26) . In addition to these domains, this molecule has several possible binding motifs for SH3 domains, and it is thus suggested that p130 may act as a ``docking protein'' in intracellular signal transduction. Thus far, the SH2 domains of Src and Crk were known to associate with p130(21, 24, 27, 28) . As for the interaction between p130 and the Src SH3 domain, there was a suggestion that the SH3 domain might be involved in the association(24, 29) , although the direct binding through SH3 domain is not proved.

To clarify the role of p130 in the oncogenic signal transduction by v-Crk or v-Src, we investigated the manner of association between p130 and v-Src or v-Crk. In this report, we demonstrate that both SH2 and SH3 domains of Src associate with the C-terminal region of p130 and determined the exact binding sites of p130 to Src. We further show that v-Crk binds to the substrate domain of p130 and that the C-terminal Src-binding region of p130 is also associated with the kinase activity in v-Crk-transformed cells.


EXPERIMENTAL PROCEDURES

Cell Lines and Antibodies

3Y1-Crk is an isolated clone of rat 3Y1 cells (30) transfected with v-crk cDNA (2) of an avian sarcoma virus, CT10, inserted in an expression vector, pMV-7 (31) . SR-3Y1 (32) is a 3Y1-derived cell line transformed by the v-Src allele of Rous sarcoma virus. Stable transformants of NIH 3T3 cells transfected with v-crk (3T3-v-Crk) were established as described(18) . Mouse monoclonal antibodies against phosphotyrosines (4G10) (33) were collected from culture supernatant of hybridoma cells. Anti-Cas2 is a polyclonal antibody against p130(18) . alphaHcrk is a rabbit polyclonal antibody against v-Crk protein and is described elsewhere(18) . mAb 327 is a monoclonal antibody against Src (34) and is kindly provided by J. S. Brugge.

In Vitro Mutagenesis of p130 and Construction of Eukaryotic Expression Vectors

The short form of the cDNA of p130(18) was cloned into M13mp19 vector. To make DeltaSH3, DeltaP1, and DeltaSD constructs, several in-frame SalI/HincII restriction sites were introduced by the site-directed mutagenesis method using an M13 in vitro mutagenesis kit (Bio-Rad). Deletion mutants were made by cutting out SalI fragments from mutated clones. The nucleotides corresponding to amino acid residues 640-642 were converted from PLP to LGS by site-directed mutagenesis to make the RPLP* mutant. Tyr, Tyr, and both tyrosine residues are similarly mutated to phenylalanine to construct Y751F, Y762F, and Y751F/Y762F mutants, respectively. The DeltaSB construct was made by cutting out a HindIII fragment from p130 cDNA. The wild-type and mutated p130 cDNAs were cloned into pSSRalpha vector (35) to make eukaryotic expression vectors.

A eukaryotic GST (glutathione S-transferase) fusion expression vector, pEBG and pEBG-p130 (36) are generous gifts from B. J. Mayer. Mutations of the p130 moiety, described above, were also introduced into this vector.

Construction of Bacterial Expression Vectors for GST Fusion Proteins

GST fusion constructs of several subregions of p130 were constructed by subcloning fragments of p130 cDNA into the SmaI site of pGEX-3X vector. To make GST-SB and GST-RPLP* constructs, PvuII fragments corresponding to residues 693-797 of wild-type p130 and RPLP* construct were cloned into the SmaI site of pGEX-3X vector.

To make GST-SrcSH2, the XhoI-MluI fragment of D3 mutant of chicken c-src(6) was blunt-ended with Klenow fragment of Escherichia coli and was cloned into the SmaI site of pGEX-1. For GST-CrkSH2 fusion protein, the SfiI-Eco81I fragment of v-crk was blunt-ended with the Klenow fragment of E. coli and ligated to the SmaI site of pGEX-1. To generate GST-SrcSH3 protein and GST-CrkSH3 protein, oligonucleotides flanking SH3 domains of c-Src (residues 81-140) and v-Crk (residues 357-440) and introducing restriction sites were used for polymerase chian reaction, and the products were cloned into BamHI-EcoRI sites of pGEX-1 and pGEX-2T, respectively. GST-Grb2/AshSH2 is a kind gift from T. Takenawa.

In Vitro Binding Assays between GST Fusion Proteins

GST fusion proteins were expressed in E. coli and purified by affinity chromatography using immobilized glutathione-Sepharose 4B beads (Pharmacia Biotech Inc.). One hundred twenty µg of the purified GST fusion proteins of domains of p130 were reacted with 20 µl of activated CNBr-Sepharose 4B (Pharmacia), following the manufacturer's instructions. Optical density of the supernatant of the reaction mixture at 260 nm ascertained that more than 95% of the fusion proteins were bound. The beads were washed twice with 2% SDS solution to reduce the nonspecific binding and reacted with 8 µg of GST-SrcSH3 fusion protein in 100 µl of 25% sucrose, 50 mM Tris, pH 7.4, 150 mM NaCl for 2 h. They were washed four times with radioimmune precipitation buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 1% Triton X-100, 10 units/ml aprotinin, 2 mM phenylmethylsulfonyl fluoride, 1 mM Na(3)VO(4)) and eluted by 60 µl of 1% SDS. The eluate was mixed with 20 µl of 4times sample buffer (8% SDS, 0.4 M Tris-HCl, pH 6.8, 10% glycerol, 0.04% bromphenol blue, and 0.4 M dithiothreitol) and analyzed by 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie Blue staining.

Transient Expression of Mutated p130 in COS-1 Cells or in 3T3 Cell Lines

COS-1 cells were transfected by the DEAE-dextran method. In brief, cells were cultured in a 15-cm dish to semiconfluent (approximately 2 times 10^6 cells/dish), and 50 µg of plasmid DNA was added with DEAE-dextran for 2.5 h and then cultured for 72 h. In the case of pSSRalpha-527F-c-Src and pSSRalpha-v-Crk, the added plasmid DNA was 5 and 25 µg, respectively. In the case of pSSRalpha-527F-c-Src and pSSRalpha-vCrk, the added plasmid DNA was 5 and 25 µg, respectively. 3T3-v-Crk cells were transfected with 22.5 µg of plasmid DNA/15-cm dish using the CaPO(4) method and cultured for 48 h.

Immunoprecipitation and Western Blotting

For protein analysis, cells were lysed in 1% Triton buffer (10 mM Tris-HCl, pH 7.4, 5 mM EDTA, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 10 µg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, and 1 mM Na(3)VO(4)).

For immunoprecipitations, 250 µl of 3Y1 cell lysates or 100 µl of COS-1 cell lysates (approximately 4 µg/µl) were mixed with 5 µl of anti-Cas2 and incubated for 1 h at 4 °C. Samples were rotated with protein A-Sepharose (Sigma) for 1 h at 4 °C, and then the beads were washed four times with 1% Triton buffer and boiled in 1 times sample buffer. Western blotting was performed as described (37) using anti-Cas2 (1:2500), 4G10 (5 µg IgG/ml) as first antibodies and detected by ProtoBlot Western AP system (Promega). In some cases, Western blotting was performed using anti-Cas2 (1:50,000), 4G10 (0.5 µg/ml IgG), or mAb 327 (1:5,000) as first antibodies and detected by ECL Western blotting analysis system (Amersham Corp.).

Affinity Precipitation with GST Fusion Proteins

Bacterial lysates including approximately 200 µg of GST-SH2 or SH3 fusion proteins were reacted with glutathione-Sepharose 4B beads (Pharmacia), and the beads were incubated with cell lysates of transformed 3Y1 cells or transfected COS-1 cells. After 1 h of incubation at 4 °C, the beads were washed four times with 1% Triton buffer and boiled in 1 times sample buffer. The proteins were separated on a 7.5% SDS-polyacrylamide gel. Western blotting was performed as described above.

In Vitro Kinase Reaction

3T3-v-Crk cells transfected with the mutants of p130 cDNA were lysed in 1% Triton-X buffer and incubated with 20 µl of glutathione-Sepharose 4B beads for 1 h at 4 °C. The beads were washed four times with 1% Triton-X buffer and twice with kinase buffer (50 mM Tris-HCl, pH 7.4, 50 mM NaCl, 10 mM MgCl(2), 10 mM MnCl(2)) and resuspended in 30 µl of kinase buffer. Kinase reaction was performed with or without 20 µg of poly-Glu-Tyr (Sigma) at room temperature for 30 min. After adding 30 µl of 4 times sample buffer, samples were separated by SDS-PAGE. Gels were fixed and incubated in 1 N KOH for 1 h at 55 °C, to reduce backgrounds derived from phosphorylated serines and threonines, before autoradiography.

Silver staining for checking the expression levels was performed as described(38) .


RESULTS

In Vitro Association of SH2 and SH3 Domains of Src and Crk with p130

GST fusion proteins containing the SH2 or SH3 domains of Src or Crk were constructed to determine which domains of Src and Crk are involved in the association with p130. GST fusion proteins were immobilized on glutathione-Sepharose beads and incubated with lysates of 3Y1, 3Y1-Crk, and SR-3Y1. After washing the beads, affinity-purified proteins with GST-fusion proteins were subjected to SDS-PAGE and Western blotting using anti-Cas2. In normal 3Y1 cells, p130 can be detected as A and B forms (Fig. 1, lane 1), and in 3Y1-Crk cells, a broad band of the C form appears (Fig. 1, lane 3). The A and B forms are regarded as the tyrosine-unphosphorylated forms, and the C form that appears as a broad smear is regarded as the tyrosine-phosphorylated form, which includes various numbers of phosphorylated tyrosines(18, 19) . Although marked tyrosine phosphorylation of p130 is detected in SR-3Y1 cells, the position of the phosphorylated band is lower than that of the C-form of p130 detected in 3Y1-Crk cells (Fig. 1, lane 2)(18) .


Figure 1: Association of p130 with SH2 or SH3 domains of Src and Crk in vitro. Cell lysates of 3Y1-vec (lanes 1, 4, 7, 10, 13, 16, and 19), SR-3Y1 (lanes 2, 5, 8, 11, 14, 17, and 20), 3Y1-Crk (lanes 3, 6, 9, 12, 15, 18, and 21) were precipitated with anti-Cas2 (lanes 1, 2, and 3), GST-SrcSH2 (lanes 4, 5, and 6), GST-SrcSH3 (lanes 7, 8, and 9), GST-CrkSH2 (lanes 13, 14, and 15), GST-CrkSH3 (lanes 16, 17, and 18), and as a negative control GST (lanes 10, 11, and 12) and GST-Grb2/AshSH2(lanes 19, 20, and 21). Immunoblotting was performed using anti-Cas2.



Both GST-SrcSH2 and GST-CrkSH2 bound to the C form of p130 but not to the A or B form (Fig. 1, lanes 4-6 and 16-18). GST-SrcSH3 bound to the A, B, and C forms of p130 (Fig. 1, lanes 7-9). We could not detect the binding of GST-CrkSH3 to p130 (Fig. 1, lanes 19-21). Negative controls, GST and GST-Grb2/AshSH2, did not bind p130 (Fig. 1, lanes 10-12 and 13-15). From these results, we concluded that the SH2 domains of Src and Crk are associated with p130 in a phosphorylation-dependent manner and that the Src SH3 domain can be associated with p130 in a phosphorylation-independent manner.

Association of the Src SH3 Domain with the C-terminal Proline-rich Region of p130

The short form of p130 cDNA (18) was used for construction of a series of deletion mutants of p130 (Fig. 2A), since it could encode a 120-kDa gene product, which corresponds to the B form of p130. These mutants were transiently expressed in COS-1 cells, and the cell lysates were reacted with immobilized GST-SrcSH3 fusion proteins to determine the binding site of the Src SH3 domain to p130 (Fig. 3A). GST-SrcSH3 failed to bind DeltaSB mutant (Fig. 3A, lanes 11 and 12), although it bound the wild-type p130 (Fig. 3A, lanes 3 and 4) and the other deletion mutants including the DeltaP1 mutant, which lacks a proline-rich region following the SH3 domain (Fig. 3A, lanes 5-10). The endogenous p130 was seen on longer exposure (data not shown).


Figure 2: A schematic diagram representing the various p130 constructs used. A, p130 constructs for eukaryotic expression vectors. These mutant constructs were introduced to pSSRalpha vector. P1 and P2 indicate two proline-rich regions that can be considered to match the consensus sequence for the SH3-binding site. Eukaryotic GST fusion protein expression vectors were constructed by exchanging the p130 moiety of pEBG-p130 (36) with these mutants. B, GST-p130 constructs for bacterial expression system.




Figure 3: Binding of GST-SrcSH3 to wild-type and mutant forms of p130 expressed in COS-1 cells. The migrations (in thousands) of molecular weight standards are indicated on the left. A, anti-Cas2 immunoblot. Approximately 500 µg of cellular lysates from COS-1 cells transiently transfected with the expression vectors for p130 mutants were immunoprecipitated with anti-Cas2 (lanes 1, 3, 5, 7, 9, and 11) or recombinant GST-SrcSH3 immobilized on glutathione-Sepharose beads (lanes 2, 4, 6, 8, 10, and 12). The transfected constructs are mock (lanes 1 and 2), wild-type p130 (lanes 3 and 4), DeltaSH3 (lanes 5 and 6), DeltaP1 (lanes 7 and 8), DeltaSD (lanes 9 and 10), and DeltaSB (lanes 11 and 12). B, anti-Cas2 immunoblot. Cellular lysates from COS-1 cells were immunoprecipitated with anti-Cas2 (lanes 13, 15, and 19), or recombinant GST-SrcSH3 (lanes 14, 16, and 20), recombinant GST-W119ASrcSH3 (lane 17), or GST (lane 18) immobilized on glutathione-Sepharose beads. The transfected constructs were mock (lanes 13 and 14), wild-type p130 (lanes 15-18), and RPLP* (lanes 19 and 20).



The deleted region in DeltaSB mutant contains the sequence RPLPSPPKF, corresponding to residues 733-741. This sequence is close to the class I consensus sequence, RXLPPLPR ( represents a hydrophobic residue) for the Src SH3 domain(39, 40) . A mutant RPLP* (Fig. 2A), in which the RPLPSPPKF sequence was converted to RSLGSPPKF, was expressed in COS-1 cells. GST-SrcSH3 fusion protein failed to bind this mutant (Fig. 3B, lanes 19 and 20). Thus, we located the binding site of the Src SH3 domain to the RPLPSPPKF sequence of p130. Furthermore, the W119A mutant of c-Src(6) , which has an alanine residue instead of the tryptophan residue well conserved in various SH3 domains, failed to bind the wild-type p130 (Fig. 3B, lane 17), confirming that this tryptophan is essential to the binding of the Src SH3 domain with p130.

In Vitro Binding of the Src SH3 domain with GST-p130 Fusion Proteins

To verify that the Src SH3 domain directly binds p130, affinity between purified GST-SrcSH3 fusion protein and purified GST-fusion proteins containing various parts of p130 (Fig. 2B) was examined. GST-SB construct of p130 was shown to bind GST-SrcSH3 (Fig. 4, lane 3), indicating that the association between p130 and the Src SH3 domain is direct. RPLP* mutant did not bind GST-SrcSH3 (Fig. 4, lane 4), confirming that this site is involved in the binding.


Figure 4: Binding of GST-SrcSH3 or GST-W119ASrcSH3 to bacterially expressed GST-p130 constructs. The position of GST-SrcSH3 and GST-W119ASrcSH3 is indicated on the left. Bacterially expressed GST-p130 constructs were purified with glutathione-Sepharose beads and eluted using glutathione. The eluted solution was dialyzed in boric acid buffer. Purified GST-SrcSH3 or GST-W119ASrcSH3 was reacted with these proteins immobilized on CNBr-activated Sepharose beads, washed four times with radioimmune precipitation buffer, and resuspended in 1% SDS solution. Samples were separated with SDS-PAGE and visualized by Coomassie Blue staining. The immobilized proteins were GST-SDa (lane 1), GST-SDb (lane 2), GST-SB (lanes 3 and 5), and GST-SB-RPLP* (lane 4). The reacted proteins were GST-SrcSH3 (lanes 1-4) and GST-W119ASrcSH3 (lane 5). One-fourth of mixed GST-SrcSH3 (lane 6), or GST-W119ASrcSH3 (lane 7) fusion proteins were also electrophoresed.



Association between p130 and 527F-c-Src Expressed in COS-1 Cells

To investigate the association of p130 with Src in vivo, the mutants of p130 and activated chicken c-Src (527F-c-Src) were co-expressed in COS-1 cells, and the lysates were immunoprecipitated with anti-Cas2 antibody. Each p130 mutant expressed (Fig. 5C) was tyrosine-phosphorylated to each extent (Fig. 5D) by 527F-c-Src, although the phosphorylation level of DeltaSB mutant was hardly detectable (Fig. 5D, lane 2). The expression of 527F-c-Src was comparable among the samples (Fig. 5B). In the case of wild-type p130, 527F-c-Src was detected in the complex immunoprecipitated with anti-Cas2 (Fig. 5A, lane 3); however, the DeltaSB mutant and RPLP* mutant showed extremely reduced amounts of the associated Src in anti-Cas2 immunoprecipitants (Fig. 5A, lanes 2 and 4). These results suggest that the interaction through the Src SH3 domain should be critical for the association between both proteins in vivo.


Figure 5: Association between 527F-c-Src and p130 mutants co-expressed in COS-1 cells. COS-1 cells were transiently transfected with pSSRalpha-527F-c-Src plus pSSRalpha-wild-type p130 or its mutants. The transfected p130 constructs were DeltaSD (lane 1), DeltaSB (lane 2), wild-type p130 (lane 3), RPLP* (lane 4), Y751F (lane 5), Y762F (lane 6), and Y751F Y762F (lane 7). After 72 h, cell lysates were collected and, 100 µl (approximately 500 µg) of lysates were immunoprecipitated with anti-Cas2. Immunoblotting was performed using mAb 327 (A), anti-Cas2 (C), 4G10 (D). Total lysates were electrophoresed and immunoblotted by mAb 327 (B) to confirm that the expression levels of 527F-c-Src were comparable.



To elucidate the interaction through the SH2 domain, another series of mutants, of which tyrosine residues were converted to phenylalanine residues, were constructed and co-expressed in COS-1 cells with 527F-c-Src. The mutation of Tyr of p130 to Phe reduced the binding ability to 527F-c-Src to less than one-third of that of the wild type (Fig. 5A, lane 6), but deletion of the substrate domain and the mutation of Tyr to Phe did not reduce the binding ability at all (Fig. 5A, lane 5). These results suggest that Tyr also contributes to the binding with 527F-c-Src. Since SH2 domains are considered to bind phosphorylated tyrosine residues, Tyr should be the binding site for the Src SH2 domain in vivo.

Association between p130 and v-Crk Expressed in COS-1 Cells

The substrate domain of p130 has repetitive YXXP motifs that are estimated to be the binding sites of v-Crk. We co-expressed v-Crk and mutants of p130 in COS-1 cells to determine the binding sites of v-Crk. We used the eukaryotic GST expression system to generate mutants of p130 fused to GST (36) and precipitated the mutants with glutathione-Sepharose beads, since immunoprecipitation can mask the band corresponding to v-Crk by heavy chains of immunoglobulins on Western blots. GST-fusion proteins of wild-type p130 and DeltaSD mutant were expressed at similar protein levels (Fig. 6C), and the expression levels of v-Crk were comparable (Fig. 6B). Although the wild-type p130 bound v-Crk (Fig. 6A, lane 2), no association of v-Crk was detected with DeltaSD mutant (Fig. 6A, lane 3), suggesting that v-Crk binds to the substrate domain of p130.


Figure 6: v-Crk binds the substrate domain of p130. COS-1 cells were transiently transfected with pEBG (lane 1), pEBG-p130 (lane2), or pEBG-DeltaSD (lane 3) plus pSSRalpha-v-Crk (lanes 1, 2, and 3) or pSSRalpha-antisense-v-Crk (lane 4). Cell lysates were collected, and 500 µg of lysates were precipitated with glutathione-Sepharose beads. A, immunoblotting were performed with alphaHcrk. C, Coomassie Blue staining. B, 50 µg of total cell lysates were immunoblotted with alphaHcrk.



The Domain of p130 with the Kinase Activity in v-Crk-transformed Cells

To determine whether the C-terminal Src binding domain also plays a role in phosphorylating p130 in the process of the transformation by v-Crk, and to get insight into the kinase responsible for the phosphorylation of p130 in v-Crk-transformed cells, we investigated the in vitro kinase activity associated with the mutants of p130 expressed in 3T3-v-Crk cells(18) . To discriminate expressed mutants from endogenous p130, GST-fusion proteins of the mutants of p130 were expressed in 3T3-v-Crk cells. Lysates of cells transfected with the plasmids encoding the wild-type p130 and the mutants were precipitated with glutathione-Sepharose beads and subjected to the in vitro kinase reaction with or without poly-Glu-Tyr as substrates (Fig. 7A). The wild-type p130 showed phosphorylation of itself and of poly-Glu-Tyr (Fig. 7A, lanes 2 and 7), suggesting that the kinase activity is associated with p130 in these cells. RPLP* mutant, in which the SH3 binding site is destroyed, was associated with markedly reduced kinase activity (Fig. 7A, lanes 3 and 8), while in Y762F mutant, associated kinase activity was comparable with that in the cells expressing wild-type p130 (Fig. 7A, lanes 4 and 9). DeltaSB mutant, which lacks a region containing both SH2 and SH3 binding sites for activated c-Src, was associated with completely reduced kinase activity (Fig. 7A, lanes 5 and 10). Although the kinase(s) that phosphorylates p130 in v-Crk-transformed cells is not known, this result shows that the SH3 binding site of p130 is associated with the kinase activity, which can phosphorylate p130 at least in vitro, in the 3T3-v-Crk cells.


Figure 7: C-terminal region of p130 is also associated with kinase activity in Crk-transformed cells. A, 3T3-Crk cells were transfected eukaryotic GST fusion expression vectors carrying wild-type p130 (lanes 2 and 7), RPLP* (lanes 3 and 8), Y762F (lanes 4 and 9), DeltaSB (lanes 5 and 10) and vector alone (lanes 1 and 6). Lysates were precipitated with glutathione-Sepharose beads and washed, and in vitro kinase reaction was performed without adding substrates (lanes 1-5) or with poly-Glu-Tyr (lanes 6-10). Proteins were separated with SDS-PAGE and autoradiographed. B, silver staining of the same lysates precipitated with glutathione-Sepharose beads. Lane 1, wild-type p130; lane 2, RPLP*; lane 3, Y762F; lane 4, DeltaSB. The positions of GST-wild-type p130 and GST-DeltaSB are indicated.




DISCUSSION

p130 is a phosphoprotein that has characteristic, clustered, and repeated (I/V/L)YXXP motifs (Table 1) in its ``substrate domain'' (18) and is supposed to be an ideal substrate for tyrosine kinases including Src family kinases and Abl(25) . Furthermore, these motifs conform very well to the consensus binding sequence for the Crk SH2 domain. p130 has also a proline-rich region and several tyrosine residues near its C terminus, suggesting that this region could provide the binding sites for the SH2 and SH3 domains. Here we report that both SH2 and SH3 domains of Src tyrosine kinase bind to the C-terminal region of p130, whereas the v-Crk binds to the substrate domain through the SH2 domain.



We revealed that Tyr of p130 is one of the binding sites for Src. As SH2 domains are thought to interact with phosphorylated tyrosine, Tyr is estimated to be the binding site for the Src SH2 domain. The sequence around Tyr (Table 1) is similar to the consensus sequence for the Src SH2 domain determined by the phosphopeptide library (26) and has a hydrophobic amino acid, valine, at the +3 position. A phosphorylated tyrosine and a hydrophobic amino acid residue at the +3 position are considered to be important for the binding between SH2 domains and tyrosine-containing peptides(41) .

The binding sequence for the Src SH3 domain is a RPLPSPPKF sequence corresponding with amino acid residues 733-741 of p130. The association between purified GST-fusion proteins suggests that the interaction between the Src SH3 domain and p130 is direct and does not require any intermediate proteins. The RPLPSPP sequence of p130 matches the Class I consensus sequence for the Src SH3 domain (Table 2) determined by a biased random peptide library(39, 40) . The known ligands for the Src SH3 domain are shown in Table 2(8, 42, 43, 44) , including the RPLPSPPKF sequence of p130.



So far, three substrates for Src family kinase, AFAP-110(11, 24) , Sam68(9, 10) , and GAP-associated p62 (29, 45) were reported to interact with Src family kinase through both SH2 and SH3 domains. In these cases, mutants of Src family kinases in the SH3 domains could not tyrosine-phosphorylate these substrates(9, 24, 45) . Therefore, the interaction through SH3 domains is assumed to be involved in the substrate recognition by these kinases. In the case of p130, although a mutant in the SH3 domain of Src, which had an impaired SH3 binding ability, could tyrosine-phosphorylate p130, the phosphorylation level was reported to be low(24) . This fact suggests that the Src SH3 domain plays a role in phosphorylating p130. In this report, we show that the Src SH3 domain binds p130. Furthermore, in the co-expression system of COS-1 cells, the mutant that destroyed only the RPLPSPP sequence showed a certain level of phosphorylation; however, the mobility on SDS-PAGE had changed. Although it is possible that the mutation itself caused this change of mobility, the mobility shift may be the result of a low level of phosphorylation. We also revealed that the tyrosine kinase activity for poly-Glu-Tyr and p130 itself was associated with the RPLPSPPKF sequence of p130 in 3T3-v-Crk cells. These results suggest that the binding through the SH3 domain would be important in tyrosine-phosphorylating p130.

In our model, the binding through the Src SH3 domain is thought to have a role in substrate recognition before tyrosine phosphorylation, and the Src SH2 domain reinforces the binding after tyrosine phosphorylation. As a result, the two-site binding interaction creates a strong association between Src and p130. This tight association may cause the effective hyperphosphorylation of p130 by Src tyrosine kinase. In the association between c-Src and p130, p130 might open the ``closed form'' of c-Src by binding to the regulatory domain and up-regulate the kinase activity of c-Src. This possibility still remains under investigation now. Tyrosine phosphorylation of p130 should allow the recruitment of SH2-domain-containing signaling molecules such as c-Crk (46) or Nck (47) and their associated proteins. This might enable these proteins to be tyrosine-phosphorylated by Src or to interact with the molecules associated with the SH3 domain of p130. Thus, p130 may serve as a ``docking protein'' linking Src to downstream signaling molecules. To clarify the role of p130 in transformation, we are now searching the molecules that comprise the complex with p130.

Although we revealed that the W119A mutant of the Src SH3 domain fails to bind p130, the W119A mutant of 527F-c-Src had a full transforming activity compared with parental 527F-c-Src(6, 7) . At present, we have no evidence to tell whether the binding of p130 to the Src SH3 domain controls the kinase activity of Src positively or negatively. There are several proteins that bind the Src SH3 domains other than p130. The cooperative roles of these molecules on the regulation of the transforming activity of Src oncoprotein should be elucidated.

In the transformation by v-Crk, the tyrosine kinase that phosphorylates p130 is not known. In this report, we reveal that most of the tyrosine kinase activity in v-Crk-transformed cells is also associated with the Src-binding C-terminal region of p130, especially the RPLPSPP sequence. This suggests that the binding of some kinase(s) to this sequence through the SH3 domain like Src kinase plays a role in phosphorylating p130. Formerly, it was reported that v-Crk caused the elevation of the co-overexpressed c-Src kinase activity in 3Y1 cells (48) . In our previous reports, co-overexpression of c-Src in v-Crk-transformed NIH 3T3 cells raised the tyrosine phosphorylation of p130(18) , and p130 could be a substrate for c-Src in vitro(19) , suggesting that c-Src might be the kinase to phosphorylate p130. We showed here that the p130-associated tyrosine kinase activity in v-Crk-transformed cells is mostly associated with the Src-binding region of p130, whereas v-Crk binds the substrate domain of p130. Therefore, the kinase activity that we see here is more likely to be caused by some other kinases that bind the Src-binding region of p130 rather than by v-Crk-associated kinases such as Abl(36, 49, 50) . However, our data cannot exclude the possibility that some tyrosine kinase that does not form a stable complex with p130 phosphorylates p130 in 3T3-v-Crk cells. We are now searching for the kinase that tyrosine-phosphorylates p130 in v-Crk-transformed cells. Furthermore, the mechanism by which v-Crk activates the tyrosine kinase and the pathway through which the phosphorylation of p130 is involved in the cell transformation should be elucidated.

Our results give an insight into the mechanism of signal transduction in v-Src- and v-Crk-transformed cells and also provide information on the physiological role of unphosphorylated p130 as a partner of tyrosine kinase.


FOOTNOTES

*
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: The Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan. Tel.: 81-3-3815-5411 (ext. 3102 or 3116); Fax: 81-3-5689-7286; hhirai-tky{at}umin.u-tokyo.ac.jp.

(^1)
The abbreviations used are: SH2, SH3, Src homology 2 and 3, respectively; mAb, monoclonal antibody; GST, glutathione S-transferase; PAGE, polyacrylamide gel electrophoresis.


ACKNOWLEDGEMENTS

We thank B. J. Mayer, J. S. Brugge, and T. Takenawa for providing pEBG-p130, mAb 327, and GST-Grb2/AshSH2, respectively.


REFERENCES

  1. Sadowski, I., Stone, J. C., and Pawson, T. (1986) Mol. Cell. Biol. 6, 4396-4408 [Medline] [Order article via Infotrieve]
  2. Mayer, B. J., Hamaguchi, M., and Hanafusa, H. (1988) Nature 332, 272-275 [CrossRef][Medline] [Order article via Infotrieve]
  3. Koch, C. A., Anderson, D., Moran, M. F., Ellis, C., and Pawson, T. (1991) Science 252, 668-674 [Medline] [Order article via Infotrieve]
  4. Cicchetti, P., Mayer, B. J., Thiel, G., and Baltimore, D. (1992) Science 257, 803-806 [Medline] [Order article via Infotrieve]
  5. Superti-Furga, G., Fumagalli, S., Koegl, M., Courtneidge, S. A., and Draetta, G. (1993) EMBO J. 12, 2625-2634 [Abstract]
  6. Hirai, H., and Varmus, H. E. (1990) Mol. Cell. Biol. 10, 1307-1318 [Medline] [Order article via Infotrieve]
  7. Hirai, H., and Varmus, H. E. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8592-8596 [Abstract]
  8. Liu, X., Marengere, L. E. M., Koch, C. A., and Pawson, T. (1993) Mol. Cell. Biol. 13, 5225-5232 [Abstract]
  9. Taylor, S. J. (1994) Nature 368, 867-871 [CrossRef][Medline] [Order article via Infotrieve]
  10. Fumagalli, S., Totty, N. F., Hsuan, J. J., and Courtneidge, S. A. (1994) Nature 368, 871-874 [CrossRef][Medline] [Order article via Infotrieve]
  11. Flynn, D. C., Leu, T. H., Reynolds, A. B., and Parsons, J. T. (1993) Mol. Cell. Biol. 13, 7892-7900 [Abstract]
  12. Lehmann, J. M., Riethmuller, G., and Jonson, J. P. (1990) Nucleic Acids Res. 18, 1048 [Medline] [Order article via Infotrieve]
  13. Clark, S. G., Stern, M. J., and Horvitz, H. R. (1992) Nature 356, 340-344 [CrossRef][Medline] [Order article via Infotrieve]
  14. Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., Ullrich, A., Skolnik, E. Y., Bar-Sagi, D., and Schlessinger, J. (1992) Cell 70, 431-442 [Medline] [Order article via Infotrieve]
  15. Matuoka, K., Shibata, M., Yamakawa, A., and Takenawa, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9015-9019 [Abstract]
  16. Matsuda, M., Mayer, B. J., Fukui, Y., and Hanafusa H. (1990) Science 248, 1537-1539 [Medline] [Order article via Infotrieve]
  17. Birge, R. B., Fajardo, J. E., Mayer, B. J., and Hanafusa, H. (1992) J. Biol. Chem 267, 10588-10595 [Abstract/Free Full Text]
  18. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756 [Abstract]
  19. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Nishida, J., Yazaki, Y., and Hirai, H. (1994) J. Biol. Chem. 269, 32740-32746 [Abstract/Free Full Text]
  20. Moran, M. F., Koch, C. A., Anderson, D., Ellis, C., England, L., Martin, G. S., and Pawson, T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8622-8626 [Abstract]
  21. Koch, C. A., Moran, M. F., Anderson, D., Liu, X., Mbamalu, G., and Pawson, T. (1992) Mol. Cell. Biol. 12, 1366-1374 [Abstract]
  22. Reynolds, A. B., Kanner, S. B., Wang, H. C. R., and Parsons, J. T. (1989) Mol. Cell. Biol. 9, 3951-3958 [Medline] [Order article via Infotrieve]
  23. Kanner, S. B., Reynolds, A. B., Vines, R. R., and Parsons, J. T. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3328-3332 [Abstract]
  24. Kanner, S. B., Reynolds, A. B., Wang, H. C. R., Vines, R. R., and Parsons, J. T. (1991) EMBO J. 10, 1689-1698 [Abstract]
  25. Songyang, Z., Carraway, K. L., III, Eck, M. J., Harrison, S. C., Feldman, R. A., Mhammadi, M., Schlessinger, J., Hubbard, S. R., Smith, D. P., Eng, C., Lorenzo, M. J., Ponder, B. A. J., Mayer, B. J., and Cantley, L. C. (1995) Nature 373, 536-539 [CrossRef][Medline] [Order article via Infotrieve]
  26. Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F., Roberts, T., Ratnofsky, S., Lechleider, R. J., Neel, B. G., Birge, R. B., Fajardo, J. E., Chou, M. M., Hanafusa, H., Schaffhausen, B., and Cantley, L. C. (1993) Cell 72, 767-778 [Medline] [Order article via Infotrieve]
  27. Matsuda, M., Mayer, B. J., and Hanafusa, H. (1991) Mol. Cell. Biol. 11, 1607-1613 [Medline] [Order article via Infotrieve]
  28. Birge, R. B., Fajardo, J. E., Reichman, C., Shoelson, S. E., Songyang, Z., Cantley, L. C., and Hanafusa, H. (1993) Mol. Cell. Biol. 13, 4648-4656 [Abstract]
  29. Weng, Z., Thomas, S. M., Rickles, R. J., Taylor, J. A., Brauer, A. W., Seidel-dugan, C. S., Michael, W. M., Dreyfuss, G., and Brugge, J. S. (1994) Mol. Cell. Biol. 14, 4509-4521 [Abstract]
  30. Kimura, G., Itagaki, A., and Summers, J. (1975) Int. J. Cancer 15, 694-706 [Medline] [Order article via Infotrieve]
  31. Kirschmeier, P. T., Housey, G. M., Johnson, M. D., Perkins, A. S., and Weinstein, I. B. (1988) DNA (N. Y.) 7, 219-225
  32. Zaitsu, H., Tanaka, H., Mitsudomi, T., Matsuzaki, A., Ohtsu, M., and Kimura, G. (1988) Biomed. Res. 9, 181-197
  33. Morrison, D. K., Kaplan, D. R., Rhee, S. G., and Williams, L. T. (1990) Mol. Cell. Biol. 10, 2359-2366 [Medline] [Order article via Infotrieve]
  34. Lipsich, L. A., Lewis, A. J., and Brugge, J. S. (1983) J. Virol. 48, 352-360 [Medline] [Order article via Infotrieve]
  35. Toyoshima, H., Kozutsumi, H., Maru, Y., Hagiwara, K., Furuya, A., Mioh, H., and Hanai, N., Takaku, F., Yazaki, Y., and Hirai, H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5404-5408 [Abstract]
  36. Mayer, B. J., Hirai, H., and Sakai, R. (1995) Curr. Biol. 5, 296-305 [Medline] [Order article via Infotrieve]
  37. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl Acad. Sci. U. S. A. 76, 4350-4354 [Abstract]
  38. Hochstrasser, D. F., Harrington, M. G., Hochstrasser, A. C, Miller, M. J., and Merril, C. R. (1988) Anal. Biochem. 173, 424-435 [Medline] [Order article via Infotrieve]
  39. Yu, H., Chen, J. K., Feng, S., Dalgarno, D. C., Brauer, A. W., and Schreiber, A. W. (1994) Cell 76, 933-945 [Medline] [Order article via Infotrieve]
  40. Feng, S., Chen, J. K., Yu, H., Simon, J. A., and Schreiber, S. L. (1994) Science 266, 1241-1247 [Medline] [Order article via Infotrieve]
  41. Waksman, G., Shoelson, S. E., Pant, N., Cowburn, D., and Kuriyan, J. (1993) Cell 72, 779-790 [Medline] [Order article via Infotrieve]
  42. Gout, I., Dhand, R., Hiles, I. D., Fry, M. J., Panayotou, G., Das, P., Truong, O., Totty, N. F., Hsuan, J., Booker, G. W., Campbell, I. D., and Waterfield, M. D. (1993) Cell 75, 25-36 [Medline] [Order article via Infotrieve]
  43. Barfod, E. T., Zheng, Y., Kuang, W. J., Hart, M. J., Evans, T., Cerione, R. A., and Ashkenazi, A. (1993) J. Biol. Chem. 268, 26059-26062 [Abstract/Free Full Text]
  44. Sudol, M. (1994) Oncogene 9, 2145-2152 [Medline] [Order article via Infotrieve]
  45. Richard, S., Yu, D., Blumer, K. J., Hausladen, D., Olszowy, M. W., Connelly, P. A., and Shaw, A. S. (1995) Mol. Cell. Biol. 15, 186-197 [Abstract]
  46. Ogawa, S., Toyoshima, H., Kozutsumi, H., Hagiwara, K., Sakai, R., Tanaka, T., Hirano, N., Mano, H., Yazaki, Y., and Hirai, H. (1994) Oncogene 9, 1669-1678 [Medline] [Order article via Infotrieve]
  47. Chou, M. M., Fajardo, J. E., and Hanafusa, H. (1992) Mol. Cell. Biol. 12, 5834-5842 [Abstract]
  48. Sabe, H., Okada, M., Nakagawa, H., and Hanafusa, H. (1992) Mol. Cell. Biol. 12, 4706-4713 [Abstract]
  49. Feller, S. M., Knudsen, B., and Hanafusa, H. (1994) EMBO J. 13, 2341-2351 [Abstract]
  50. Ren, R., Ye, Z. S., and Baltimore, D. (1994) Genes & Dev. 8, 783-795

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.